Merck KGaA (Merck KGaA) 6-1 Month Momentum % : 13.37% (As of Apr. 27, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Merck KGaA 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-27), Merck KGaA's 6-1 Month Momentum % is 13.37%.

The industry rank for Merck KGaA's 6-1 Month Momentum % or its related term are showing as below:

MKKGY's 6-1 Month Momentum % is ranked better than
59.44% of 1112 companies
in the Drug Manufacturers industry
Industry Median: 3.415 vs MKKGY: 13.37

Competitive Comparison of Merck KGaA's 6-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merck KGaA's 6-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Merck KGaA's 6-1 Month Momentum % falls into.

Merck KGaA (OTCPK:MKKGY) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA (OTCPK:MKKGY) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Merck KGaA 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Merck KGaA's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck KGaA (Merck KGaA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck KGaA (OTCPK:MKKGY) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

MKGAF:USA MRK:Italy MRKd:UK 0O14:UK MRK:Germany MRCK:Austria

Address

Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293

Website

https://www.emdgroup.com

Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (47% of 2022 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (35%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.